Tag Archive for: Acquisition

Peter Llewellyn-Davies, CEO of Apeiron Biologics and co-founder of the Austrian Biotech Association (right) with Dr Romana Gugenberger as Chief Medical & Scientific Officer (CMSO) and Dr Andreas Gerber,, Chief Operating Officer (COO) in 2021. @ Apeiron Biologics AG

Austrian Apeiron Biologics goes to Ligand Pharmaceuticals for US$100m.

Gerben Menschaert and Griet Nuytinck © Anthony Van Driessche

Merger within Ghent, Belgium: Anacura acquires OHMX.bio (both residing in neighborhood), adding multi-omics for drug discovery and diagnostics to its services.

© Elsie Biotechnology

GSK takes over Elsie Biotechnologies in US$50m deal to boost its oligonucleotide-based drug platform and pipeline.

Fundus in diabetis retinopathy. © By Shaofeng Hao, Changyan Liu, Na Li, Yanrong Wu, Dongdong Li, Qingyue Gao, Ziyou Yuan, Guanyan Li, Huilin Li, Jianzhou Yang, and Shengfu Fan. - (2022). - wikipedia.org/PLoS One (doi:10.1371/journal.pone.0275983.

US pharma giant Merck Sharp & Dohme (MSD) is decided to acquire London-based ophtalmology expert Eyebiotech Ltd for upt to US$3bn., US$1.7bn in future milestones.

Neuroblastoma cells (green) in the adrenal gland. Cell nuclei are coloured blue. © Charité | Anja Heeren-Hagemann

Essential Pharma has acquired Renaissance Pharma Ltd to commercialise  the company’s Phase II program Hu14.18K322A in pedriatric high-risk neuroblastoma.

Claudia Ulbrich, MD, CEO und Prof. Thomas Thum, MD, PhD, CSO/CMO at Cardior Pharmaceuticals. © Cardior Pharmaceuticals

Novo Nordisk is set to acquire German miRNA blocker specialist Cardior Pharmaceuticals GmbH for up to €1.025bn including milestone payments.

Canadian Fusion Therapeutics Inc is utilising the advantages of alpha medical isotopes to develop targeted alpha therapies. The company uses targeting molecules, such as antibodies, armed with potent alpha emitting isotopes to precisely and effectively induce cancer cell death by induction of DNA double strand breaks. © Fusion Therapeutics Inc

British pharma giant AstraZeneca has announced to acquire radio-conjugate specialist Fusion Therapeutics Inc for US$2bn upfront.

AstraZeneca Cambridge headquarters © wikipedia.org/D_Wells

French endocrine diseases specialist Amolyt Pharma SA has entered into a take-over agreement by AstraZeneca.

© Ralphs_Fotos/pixabay.com

GI specialist Ironwood Pharmaceuticals Inc. has announced to acquire Swiss VectivBio Holding AG for $17 per share in an all-cash transaction.

© mirerek8 / Pixabay

Swiss rare disease specialist VectivBio Holding AG is taking over US biotech Comet Therapeutics Inc. for an undisclosed amount. Comet focusses on treatments for metabolic diseases.